An evaluation of asciminib for patients with chronic myeloid leukemia previously treated with ≥2 tyrosine kinase inhibitors

References

• Apperley JF. Chronic myeloid leukaemia. Lancet. 2015;385:1447–1459.
   PubMed Web of Science ®Google Scholar
• Madhusudan S, Ganesan TS. Tyrosine kinase inhibitors in cancer therapy. Clin Biochem. 2004;37:618–635.
   PubMed Web of Science ®Google Scholar
• Hochhaus A, Larson RA, Guilhot F, et al. Long-term outcomes of imatinib treatment for chronic myeloid leukemia. N Engl J Med. 2017;376:917–927.
   PubMed Web of Science ®Google Scholar
• Deininger M. Resistance and relapse with imatinib in CML: causes and consequences. J Natl Compr Canc Netw. 2008;6(Suppl 2):S11–S21.
   PubMedGoogle Scholar
• Jabbour E, Kantarjian H, Cortes J. Chronic myeloid leukemia and second-generation tyrosine kinase inhibitors: when, how, and which one? Semin Hematol. 2010;47:344–353.
   PubMed Web of Science ®Google Scholar
• García-Gutiérrez V, Hernández-Boluda JC. Tyrosine kinase inhibitors available for chronic myeloid leukemia: efficacy and safety. Front Oncol. 2019;9:603.
   PubMed Web of Science ®Google Scholar
• Cortes J, Lang F. Third-line therapy for chronic myeloid leukemia: current status and future directions. J Hematol Oncol. 2021;14:44.
   PubMed Web of Science ®Google Scholar
• Hochhaus A, Baccarani M, Silver RT, et al. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia. 2020;34:966–984.
   PubMed Web of Science ®Google Scholar
• Hochhaus A, Saussele S, Rosti G, et al. Chronic myeloid leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29:iv261.
   Google Scholar
• Hochhaus A, Breccia M, Saglio G, et al. Expert opinion-management of chronic myeloid leukemia after resistance to second-generation tyrosine kinase inhibitors. Leukemia. 2020;34:1495–1502.
   PubMed Web of Science ®Google Scholar
• Khoury HJ, Cortes JE, Kantarjian HM, et al. Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure. Blood. 2012;119:3403–3412.
   PubMed Web of Science ®Google Scholar
• Cortes JE, Khoury HJ, Kantarjian HM, et al. Long-term bosutinib for chronic phase chronic myeloid leukemia after failure of imatinib plus dasatinib and/or nilotinib. Am J Hematol. 2016;91:1206–1214.
   PubMed Web of Science ®Google Scholar
• Hochhaus A, Gambacorti-Passerini C, Abboud C, et al. Bosutinib for pretreated patients with chronic phase chronic myeloid leukemia: primary results of the phase 4 BYOND study. Leukemia. 2020;34:2125–2137.
   PubMed Web of Science ®Google Scholar
• Cortes JE, Kim D-W, Pinilla-Ibarz J, et al. A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. N Engl J Med. 2013;369:1783–1796.
   PubMed Web of Science ®Google Scholar
• Cortes JE, Kim D-W, Pinilla-Ibarz J, et al. Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial. Blood. 2018;132:393–404.
   PubMed Web of Science ®Google Scholar
• Dorer DJ, Knickerbocker RK, Baccarani M, et al. Impact of dose intensity of ponatinib on selected adverse events: multivariate analyses from a pooled population of clinical trial patients. Leuk Res. 2016;48:84–91.
   PubMed Web of Science ®Google Scholar
• Cortes J, Apperley J, Lomaia E, et al. Ponatinib dose-ranging study in chronic-phase chronic myeloid leukemia: a randomized, open-label phase 2 clinical trial. Blood. 2021;138:2042–2050.
   PubMed Web of Science ®Google Scholar
• Do YR, Kwak J-Y, Kim JA, et al. Long-term data from a phase 3 study of radotinib versus imatinib in patients with newly diagnosed, chronic myeloid leukaemia in the chronic phase (RERISE). Br J Haematol. 2020;189:303–312.
   PubMedGoogle Scholar
• Kim S-H, Menon H, Jootar S, et al. Efficacy and safety of radotinib in chronic phase chronic myeloid leukemia patients with resistance or intolerance to BCR-ABL1 tyrosine kinase inhibitors. Haematologica. 2014;99:1191–1196.
   PubMed Web of Science ®Google Scholar
• Shoukier M, Kubiak M, Cortes J. Review of new-generation tyrosine kinase inhibitors for chronic myeloid leukemia. Curr Oncol Rep. 2021;23:91.
   PubMedGoogle Scholar
• Ciftciler R, Haznedaroglu IC. Tailored tyrosine kinase inhibitor (TKI) treatment of chronic myeloid leukemia (CML) based on current evidence. Eur Rev Med Pharmacol Sci. 2021;25:7787–7798.
   PubMed Web of Science ®Google Scholar
• Mueller D, Totzke F, Weber Tet al, IC50 profiling against 320 proteins kinases improving the accuracy of kinase inhibitor selectivity testing. Cancer Res. 2018; (2018) 78 (13 Supplement): 238
   Google Scholar
• Manley PW, Barys L, Cowan-Jacob SW. The specificity of asciminib, a potential treatment for chronic myeloid leukemia, as a myristate-pocket binding ABL inhibitor and analysis of its interactions with mutant forms of BCR-ABL1 kinase. Leuk Res. 2020;98:106458.
   PubMed Web of Science ®Google Scholar
• Eide CA, Zabriskie MS, Savage Stevens SL, et al. Combining the allosteric inhibitor asciminib with ponatinib suppresses emergence of and restores efficacy against highly resistant BCR-ABL1 mutants. Cancer Cell. 2019;36:431–443.e5.
   PubMed Web of Science ®Google Scholar
• Hoch M, Sato M, Zack J, et al. Pharmacokinetics of asciminib in individuals with hepatic or renal impairment. J Clin Pharmacol. 2021;61:1454–1465.
   PubMedGoogle Scholar
• Menssen HD, Quinlan M, Kemp C, et al. Relative bioavailability and food effect evaluation for 2 tablet formulations of asciminib in a 2-arm, crossover, randomized, open-label study in healthy volunteers. Clin Pharmacol Drug Dev. 2019;8:385–394.
   PubMedGoogle Scholar
• Breccia M, Colafigli G, Scalzulli E, et al. Asciminib: an investigational agent for the treatment of chronic myeloid leukemia. Expert Opin Investig Drugs. 2021;30:803–811.
   PubMedGoogle Scholar
• Hughes TP, Mauro MJ, Cortes JE, et al. Asciminib in chronic myeloid leukemia after abl kinase inhibitor failure. N Engl J Med. 2019;381:2315–2326.
   PubMed Web of Science ®Google Scholar
• Rea D, Kim D, Cortes J, et al. Asciminib, a specific allosteric BCR-ABL1 inhibitor in patients with chronic myeloid leukemia carrying the T315I mutation in a phase 1 trial. Blood. 2018;99:113609.
   Google Scholar
• Cortes JE, Lang F, Kim D-W, et al. Combination therapy using asciminib plus imatinib in patients with chronic myeloid leukemia: results from a phase 1 study. HemaSphere. 2018;2:S1, Abstract n. S883.
   PubMedGoogle Scholar
• Mauro M, kim DW, Cortes J, et al. Combination of asciminib plus nilotinib or dasatinib in patients with chronic myeloid leukemia: results from a phase 1 study. HemaSphere. 2019;2:S1, Abstract n. S884.
   Google Scholar
• Réa D, Mauro MJ, Boquimpani C, et al. A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs. Blood. 2021;138:2031–2041.
   PubMed Web of Science ®Google Scholar
• Mauro J, Minami Y, Rea D, et al. Efficacy and safety results from ascembl, a multicenter, open-label, phase 3 study of asciminib, a first-in-class STAMP inhibitor, vs bosutinib in patients with chronic myeloid leukemia in chronic phase after ≥2 prior tyrosine kinase inhibitors: update after 48 weeks. Blood. 2020;138(Supplement 1):2563
   Google Scholar
• Garcia-Gutiérrez V, Luna A, Alonso-Dominguez JM, et al. Safety and efficacy of asciminib treatment in chronic myeloid leukemia patients in real-life clinical practice. Blood Cancer J. 2021;11:16.
   PubMed Web of Science ®Google Scholar
• Pérez-Lamas L, Luna A, Boqué C. Asciminib in real-life clinical practice, safety and efficacy profile in chronic myeloid leukemia pretreated patients. Blood. 2021;138(Supplement 1):2563.
   Google Scholar
• Khadadah F, Xenocostas A, Busque L. A real-world Canadian experience of asciminib use in chronic myeloid leukemia (cml) patients who failed multiple lines of Tyrosine Kinase Inhibitor (TKI) therapy. Blood. 2021;138(Supplement 1):3610.
   Google Scholar
• Turkina AG, Shukhov OA, Lomaia E. The first results of asciminib therapy in highly pretreated chronic myeloid leukemia patients under the Managed Access Program (MAP) in Russian Federation. Blood. 2021;138(Supplement 1):1483.
   Google Scholar
• Andorsky D, Tomassetti S, Deutsch YE. Asciminib in monotherapy 4 CML (AIM4CML), a phase IIIb study of asciminib monotherapy in patients with chronic myeloid leukemia in chronic phase without or with T315I mutations. Blood. 2021;138(Supplement 1):3599.
   Google Scholar
• Asciminib treatment optimization in ≥ 3rd line CML-CP [Internet]. Available from: https://clinicaltrials.gov/ct2/results?cond=&term=NCT04948333&cntry=&state=&city=&dist=.
   Google Scholar
• Steegmann JL, Baccarani M, Breccia M, et al. European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia. Leukemia. 2016;30:1648–1671.
   PubMed Web of Science ®Google Scholar